Meeting
2020 Genitourinary Cancers Symposium
Biochemical relapse in very high-risk prostate cancer after radical prostatectomy and DC-vaccine loaded with tumor RNA, hTERT, and survivin.
Authors
Wolfgang Lilleby
Oslo University Hospital, Oslo, Norway
Wolfgang Lilleby , Anne Merete Tryggestad , Iris Bigalke , Bjørn Brennhovd , Karol Axcrona , Dag Josefsen , Ulrika Axcrona , Gunnar Kvalheim , Svein Dueland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT01197625
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 324)
Abstract #
324
Poster Bd #
M8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).
First Author: Edwin Melencio Posadas
Poster
2024 ASCO Genitourinary Cancers Symposium
Rezvilutamide in combination with androgen-deprivation therapy, with or without salvage radiotherapy, for patients experiencing biochemical recurrence following radical prostatectomy: A multi-center, open-label, two-cohort study.
First Author: Shun Zhang
Poster
2022 ASCO Genitourinary Cancers Symposium
Salvage radiotherapy (SRT) in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer.
First Author: Markus Grabbert
Poster
2021 ASCO Annual Meeting
Validation of the decipher genomic classifier (GC) in SAKK 09/10: A phase III randomized trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy (RP).
First Author: Alan Dal Pra